Indication
As add-on maintenance treatment of adult patients with uncontrolled chronic obstructive pulmonary disease (COPD) of an eosinophilic phenotype on a combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA).
Medicine details
- Medicine name:
- mepolizumab (Nucala)
- SMC ID:
- SMC2947
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Respiratory system
- Submission type
- Full
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- TBC